Cytosorbents (NASDAQ:CTSO) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Cytosorbents (NASDAQ:CTSO) announced its earnings results on Monday. The medical research company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.04, Zacks reports. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.

Cytosorbents Stock Performance

Shares of CTSO stock remained flat at $1.00 during trading on Monday. The company had a trading volume of 100,419 shares, compared to its average volume of 144,967. The stock’s 50 day simple moving average is $1.07 and its 200-day simple moving average is $1.05. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a market cap of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CTSO. StockNews.com initiated coverage on Cytosorbents in a research report on Wednesday, March 26th. They issued a “hold” rating on the stock. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.